{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:12:36Z","timestamp":1790251956985,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015676","name":"New South Wales Health Pathology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytica Chimica Acta"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.aca.2026.345222","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:19:55Z","timestamp":1770855595000},"page":"345222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Automated sample-preparation and mass spectrometry-based assays for free and total Infliximab: Enabling therapeutic drug monitoring of monoclonal antibodies"],"prefix":"10.1016","volume":"1396","author":[{"given":"Melissa J.","family":"Sam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4376-832X","authenticated-orcid":false,"given":"David G.","family":"Harman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7034-7187","authenticated-orcid":false,"given":"Catherine M.","family":"Toong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-8193","authenticated-orcid":false,"given":"William A.","family":"Donald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aca.2026.345222_bib1","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1053\/j.gastro.2022.02.014","article-title":"Optimizing therapies using therapeutic drug monitoring: current strategies and future perspectives","volume":"162","author":"Irving","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aca.2026.345222_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2025.118385","article-title":"Characterization and quantification of therapeutic monoclonal antibodies, anti-drug antibodies and their interactions for clinical applications","volume":"192","author":"Alez-Martin","year":"2025","journal-title":"TrAC, Trends Anal. Chem."},{"key":"10.1016\/j.aca.2026.345222_bib3","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.aca.2026.345222_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","article-title":"Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases","volume":"15","author":"Papamichael","year":"2019","journal-title":"Expet Rev. Clin. Immunol."},{"key":"10.1016\/j.aca.2026.345222_bib5","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.aca.2026.345222_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"The lancet. Gastroenterology & hepatology"},{"key":"10.1016\/j.aca.2026.345222_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.pathol.2020.08.020","article-title":"Comparison of three commercially available ELISA assays for anti-infliximab antibodies","volume":"53","author":"West","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.aca.2026.345222_bib8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/FTD.0000000000000795","article-title":"Comparative evaluation of 4 commercially available ELISA kits for measuring adalimumab and anti-adalimumab antibodies","volume":"42","author":"Sam","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.aca.2026.345222_bib9","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1093\/ibd\/izz202","article-title":"Infliximab and Adalimumab concentrations may vary between the enzyme-linked immunosorbent assay and the homogeneous mobility shift assay in patients with inflammatory bowel disease: a prospective cross-sectional observational study","volume":"25","author":"Clarke","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.aca.2026.345222_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179561","article-title":"Validation study of a new random-access chemiluminescence immunoassay analyzer i-TRACK10(\u00ae) to monitor infliximab and adalimumab serum trough levels and anti-drug antibodies","volume":"23","author":"Berger","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.aca.2026.345222_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jim.2011.08.022","article-title":"Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF\u03b1 antagonists","volume":"373","author":"Lallemand","year":"2011","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.aca.2026.345222_bib12","doi-asserted-by":"crossref","first-page":"19286","DOI":"10.1021\/acs.analchem.4c02932","article-title":"Therapeutic monoclonal antibody\u2500antidrug antibody affinity constant determination using capillary electrophoresis-tandem mass spectrometry","volume":"96","author":"Reinert","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.aca.2026.345222_bib13","doi-asserted-by":"crossref","first-page":"7477","DOI":"10.1007\/s00216-015-8915-8","article-title":"Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization","volume":"407","author":"Real-Fern\u00e1ndez","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.aca.2026.345222_bib14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ibd.21919","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.aca.2026.345222_bib15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/dta.1968","article-title":"Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay","volume":"9","author":"Van Stappen","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.aca.2026.345222_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"Ben-Horin","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.aca.2026.345222_bib17","first-page":"2447","article-title":"Validation of the i-Tracker drug and total anti-drug antibody CLIA assays on IDS-iSYS for therapeutic drug monitoring in Adalimumab- and infliximab-treated patients","volume":"15","author":"Dossou","year":"2025"},{"key":"10.1016\/j.aca.2026.345222_bib18","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/FTD.0000000000000553","article-title":"Discrimination of anti-drug antibodies with neutralizing capacity in Infliximab- and adalimumab-treated patients: comparison of the homogeneous mobility shift assay and the affinity capture and elution assay","volume":"40","author":"Hock","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.aca.2026.345222_bib19","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.pathol.2016.07.001","article-title":"Comparison of infliximab drug measurement across three commercially available ELISA kits","volume":"48","author":"Lee","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.aca.2026.345222_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2024.342789","article-title":"High-throughput, low-cost quantification of 11 therapeutic antibodies using caprylic acid precipitation and LC-MS\/MS","volume":"1313","author":"Hallin","year":"2024","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.aca.2026.345222_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.aca.2019.03.033","article-title":"A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: application for adalimumab therapeutic drug monitoring in patients with Crohn's disease","volume":"1067","author":"Willeman","year":"2019","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.aca.2026.345222_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.aca.2019.05.076","article-title":"Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological matrices with liquid chromatography mass spectrometry - a tutorial","volume":"1080","author":"El Amrani","year":"2019","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.aca.2026.345222_bib23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.chroma.2016.05.070","volume":"1454","author":"El Amrani","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.aca.2026.345222_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinms.2019.01.003","article-title":"An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab","volume":"12","author":"van der Gugten","year":"2019","journal-title":"Clinical mass spectrometry (Del Mar, Calif.)"},{"key":"10.1016\/j.aca.2026.345222_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.intimp.2015.07.007","article-title":"Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS\/MS","volume":"28","author":"Willrich","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.aca.2026.345222_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2019.100004","article-title":"Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry: infliximab as proof of principle","volume":"1","author":"El Amrani","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.aca.2026.345222_bib27","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/FTD.0000000000000633","article-title":"Simultaneous quantification of free adalimumab and Infliximab in human plasma using a target-based sample purification and liquid chromatography-tandem mass spectrometry","volume":"41","author":"El Amrani","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.aca.2026.345222_bib28","series-title":"Rational Design of Fast Cubic Chromatographic Gradients for Multi-analyte Analysis Applied to Clinical LC-MS","author":"Hodgkins M","year":"2025"},{"key":"10.1016\/j.aca.2026.345222_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FTD.0000000000001204","article-title":"Best practice for therapeutic drug monitoring of infliximab: position statement from the International association of therapeutic drug monitoring and clinical toxicology","volume":"46","author":"Alsoud","year":"2024","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.aca.2026.345222_bib30","first-page":"146","article-title":"Comparison of drug tolerant assays for the measurement of bound anti-infliximab antibodies in patient serum","volume":"39","author":"Sam K","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.aca.2026.345222_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jim.2019.06.014","article-title":"Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS","volume":"472","author":"Iwamoto","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.aca.2026.345222_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jmsacl.2024.01.007","article-title":"Infliximab therapeutic monitoring by tryptic peptide LC-MS\/MS method improvements lead to improved accuracy with decreased imprecision and turnaround time","volume":"32","author":"Ladwig","year":"2024","journal-title":"J. mass spectrometry and adv. clinical lab"},{"key":"10.1016\/j.aca.2026.345222_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbiotec.2018.05.001","article-title":"Multiple functions of caprylic acid-induced impurity precipitation for process intensification in monoclonal antibody purification","volume":"279","author":"Trapp","year":"2018","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.aca.2026.345222_bib34","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdn054","article-title":"A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer","volume":"19","author":"Brown","year":"2008","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.aca.2026.345222_bib35","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00003246-198910000-00001","article-title":"Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans","volume":"17","author":"Damas","year":"1989","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.aca.2026.345222_bib36","first-page":"2350","article-title":"High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease","volume":"97","author":"Mart\u00ednez-Borra","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.aca.2026.345222_bib37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.aca.2026.345222_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.aca.2026.345222_bib39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/apt.14410","article-title":"Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy","volume":"47","author":"Bar-Yoseph","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.aca.2026.345222_bib40","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/apt.16333","article-title":"Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease","volume":"53","author":"Tournier","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.aca.2026.345222_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(25)02941-5","article-title":"Early infliximab levels and clearance predict outcomes after infliximab Rescue in acute severe ulcerative colitis: results from PREDICT-UC","author":"Li Wai Suen","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.aca.2026.345222_bib42","doi-asserted-by":"crossref","first-page":"S053","DOI":"10.1093\/ecco-jcc\/jjy222.079","article-title":"DOP45 adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn's disease: a post-hoc analysis of the ACCENT-2 trial","volume":"13","author":"Vande Casteele","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.aca.2026.345222_bib43","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.cgh.2021.07.053","article-title":"Higher anti-tumor necrosis Factor-\u03b1 levels correlate with improved radiologic outcomes in Crohn's perianal fistulas","volume":"20","author":"De Gregorio","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.aca.2026.345222_bib44","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1007\/s00216-023-04963-6","article-title":"Simultaneous quantification of total and free testosterone in human serum by LC\u2013MS\/MS","volume":"415","author":"Huang","year":"2023","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.aca.2026.345222_bib45","first-page":"198","volume":"vol. 22","author":"Wu","year":"2013"}],"container-title":["Analytica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003267026001728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003267026001728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:40:01Z","timestamp":1774014001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003267026001728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":45,"alternative-id":["S0003267026001728"],"URL":"https:\/\/doi.org\/10.1016\/j.aca.2026.345222","relation":{},"ISSN":["0003-2670"],"issn-type":[{"value":"0003-2670","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Automated sample-preparation and mass spectrometry-based assays for free and total Infliximab: Enabling therapeutic drug monitoring of monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Analytica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aca.2026.345222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"345222"}}